Senior Leadership

高级领导 斯坦顿湖格尔森，医学博士，主任，病例综合癌症中心（病例CCC） 博士格尔森被任命为病例综合癌症中心主任和副院长 2004年9月，肿瘤学。 资历：Gerson博士是造血和免疫细胞生物学项目负责人 1992年至2004年担任项目主任，1995年至2004年担任临床研究副主任。他是 晋升为终身教授于1993年，被任命为血液肿瘤学Shiverick教授， 1997年，当选为美国医师协会。Gerson博士成为了 1995年，血液肿瘤科。Gerson博士为NIH同行提供了广泛的服务 审查过程，自1989年以来担任实验治疗学研究部分的特设审查员 1997-2002年（2000-2002年担任主席）; 2001-2005年担任RAID方案SAB; 计划项目研究部分（2004年-）;以及2005年NCI-RAID计划的NCI外部审查。 他目前担任NCI癌症中心主任工作组早期检测小组委员会主席 由医学博士John Mendelsohn主持，为NCI提供2015年计划的指导。格尔森博士 发表了超过175篇同行评审论文，并共同编辑了2篇文章，癌症的基因治疗（1999，2002） 临床血液学（2005）Gerson博士在Fox的外部咨询委员会任职 蔡斯综合癌症中心，金梅尔约翰霍普金斯综合癌症中心，和 爱荷华州综合癌症中心他花了50%的时间管理综合性的 癌症中心，35%的精力用于他的研究，10%的精力用于管理爱尔兰癌症中心，5%的精力用于他的研究。 在病人护理方面的努力。 研究成就：Gerson博士的研究集中在三个相关领域： 细胞生物学、DNA修复和与DNA修复相关的药物开发。他一直 自1984年以来一直由NIH资助。这些活动的详细情况见《概览》， 第6.7节。 权力：作为董事，Gerson博士有权批准和审查成员资格，包括 案例CCC的高级和项目负责人。他可以对中心进行主要预约， 与癌症中心的资源，促进招聘到许多主要部门的案例学校 克利夫兰大学医院的医学和临床部门。他有责任 同时担任凯斯医学院和克利夫兰大学医院的系主任。他还 积极参与Lerner研究所和Taussig Cancer的研究管理活动 通过直接参与他们的搜索委员会，并通过高级领导委员会， 癌症中心，其中包括副主任勒纳研究所和 Taussig癌症中心副主任，在确定成员的癌症研究优先事项， Cleveland Clinic的项目。机构领导人联合信函对此作了进一步界定。博士 Gerson对Case CCC的所有共享资源拥有财政和行政权力， Wolstein大楼的研究空间，生物医学研究大楼的共享资源空间， 凯斯医学院西尔斯大楼，位于韦恩的研究行政空间 克利夫兰大学医院的建设，临床肿瘤学空间和服务（医疗，放射 克利夫兰大学医院和爱尔兰大学癌症中心 医院卫生系统。此外，Gerson博士还担任克利夫兰 临床与转化科学奖（CTSA）申请由Case提交，包括附属机构 医院2006年3月Gerson博士召集案件的外部和内部咨询委员会 CCC和他们的建议，作出决定的方案，共享资源和战略规划， 中心。

SENIOR LEADERSHIP Stanton L. Gerson, MD, Director, Case Comprehensive Cancer Center (Case CCC) Dr. Gerson was named Director of the Case Comprehensive Cancer Center and Associate Dean for Oncology in September, 2004. Qualifications: Dr. Gerson was Program Leader for the Hematopoietic and Immune Cell Biology Program from 1992-2004, and Associate Director for Clinical Research from 1995-2004. He was promoted to tenured Professor in 1993, was named the Shiverick Professor for Hematological Oncology in 1997, and elected to the American Association of Physicians in 1997. Dr. Gerson became the Chief of the Division of Hematology-Oncology in 1995. Dr. Gerson has provided extensive service to the NIH peer review process, serving as ad hoc reviewer since 1989, on the Experimental Therapeutics study section from 1997-2002 (Chair from 2000-2002); the RAID program SAB from 2001-2005; Subcommittee D for the Program Projects study section (2004-); and the NCI external review for the NCI-RAID program in 2005 . He currently chairs the Early Detection Subcommittee for the NCI Cancer Center Directors Working Group chaired by John Mendelsohn, MD, to provide guidance to the NCI on the 2015 initiative. Dr. Gerson has published over 175 peer-reviewed papers, and co-edited 2 texts, Gene Therapy of Cancer (1999, 2002) and Clinical Hematology (2005). Dr. Gerson serves on the External Advisory Committees for the Fox Chase Comprehensive Cancer Center, the Kimmel Johns Hopkins Comprehensive Cancer Center, and the Iowa Comprehensive Cancer Center. He spends 50% of his time administering the Comprehensive Cancer Center, 35% effort on his research, 10% effort administering the Ireland Cancer Center, and 5% effort on patient care. Research Accomplishments: Dr. Gerson's research has focused on three related areas: stem cell biology, DNA repair, and drug development related to DNA repair as a target. He has been continuously funded by the NIH since 1984. Details of these activities are described in the Overview, section 6.7. Authority: As Director, Dr. Gerson has authority to approve and review membership including Senior and Program Leaders to the Case CCC. He can make primary appointments to the Center, and with Cancer Center resources, facilitate recruitments to many primary departments of Case School of Medicine and to Clinical Departments of University Hospitals of Cleveland. He has the responsibilities of a Department Chair at both Case School of Medicine and University Hospitals of Cleveland. He also actively participates in research administrative activities at Lerner Research Institute and Taussig Cancer Center by participating directly on their search committees, and through the Senior Leadership Committee of the Cancer Center, which includes the Associate Director for the Lerner Research Institute and the Associate Director for the Taussig Cancer Center, in setting the cancer research priorities of members and programs of the Cleveland Clinic. This is further defined in the joint institutional leadership letter. Dr. Gerson has fiscal and administrative authority over all Shared Resources of the Case CCC, 47,000 sq ft of research space in the Wolstein Building, shared resource space in the Biomedical Research Building and Sears Tower Building of the Case School of Medicine, research administrative space in the Wearn Building of University Hospitals of Cleveland, the clinical oncology space and services (medical, radiation and surgical) of University Hospitals of Cleveland and the Ireland Cancer Center sites of University Hospital Health System. In addition, Dr. Gerson serves on the Steering Committee of the Cleveland Clinical & Translational Science Award (CTSA) application submitted by Case and including the affiliated hospitals in March 2006. Dr. Gerson convenes the External and Internal Advisory Boards of the Case CCC and with their advice, makes decisions on Programs, Shared Resources and strategic planning for the Center.